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Abstract  
The late endo-/lysosomal P-type ATPase ATP13A2 (PARK9) is implicated in Parkinson’s disease (PD) 
and Kufor-Rakeb syndrome, an early-onset atypical parkinsonism. ATP13A2 interacts at the N-terminus 
with the signaling lipids phosphatidic acid (PA) and phosphatidylinositol (3,5) bisphosphate (PI(3,5)P2), 
which modulate ATP13A2 activity under cellular stress conditions. Here, we analyzed stable human 
SHSY5Y cell lines overexpressing wild-type (WT) or ATP13A2 mutants in which three N-terminal 
lipid binding sites (LBS1-3) were mutated. We explored the regulatory role of LBS1-3 in the cellular 
protection by ATP13A2 against mitochondrial stress induced by rotenone and found that the LBS2-3 
mutants displayed an abrogated protective effect. Moreover, in contrast to WT, the LBS2 and LBS3 
mutants responded poorly to pharmacological inhibition of respectively PI(3,5)P2 and PA formation. 
We further demonstrate that PA and PI(3,5)P2 are also required for the ATP13A2-mediated protection 
against the toxic metals Mn2+, Zn2+ and Fe3+, suggesting a general lipid-dependent activation mechanism 
of ATP13A2 in various PD-related stress conditions. Our results indicate that the ATP13A2-mediated 
protection requires binding of PI(3,5)P2 to LBS2 and PA to LBS3. Thus, targeting the N-terminal lipid 
binding sites of ATP13A2 might offer a therapeutic approach to reduce cellular toxicity of various PD 
insults including mitochondrial stress.   
Introduction 
Mitochondria are organelles with a pivotal role in ATP production, intracellular Ca2+ signaling, the 
generation of reactive oxygen species (ROS) and apoptotic cell death [1-3]. Because of high energy 
demands at locations distant from the cell body, neurons in particular critically depend on healthy and 
dynamic mitochondria to fuel membrane excitability and to execute neurotransmission and plasticity 
[4,5]. Not surprisingly, defective mitochondrial dynamics is implicated in various neurological 
disorders, including Parkinson’s disease (PD), a common progressive movement disorder characterized 
by a severe loss of dopaminergic neurons in the substantia nigra pars compacta [6]. PD is hallmarked 
by the accumulation of aggregated α-synuclein into Lewy bodies in neurons of the substantia nigra and 
specific brain stem, spinal cord and cortical regions [7,8], but also mitochondrial defects are common 
[9-11]. Strong support for mitochondrial dysfunction in PD comes from the observations that 1-methyl-
4-phenyl-1,2,3,4-tetrahydropyridine (MPTP), a potent mitochondrial complex I inhibitor, triggers a PD-
like syndrome [12,13]. Moreover, several PD-associated genes, mainly parkin and PINK1, play a role 
in mitochondrial dynamics and clearance via mitophagy, which strengthens the concept that 
mitochondrial dysfunction and/or impaired mitochondrial clearance are tightly linked to PD onset 
[9,10].  
In the present study, we focus on ATP13A2/PARK9, encoding a late endo-/lysosomal membrane protein, 
which belongs to a poorly characterized subfamily of P-type ATPases, namely the P5-type transporters 
with unassigned function and substrate specificity. So far, the three-dimensional structure of ATP13A2 
is unknown, but can be modelled based on the known structures of other P-type ATPases (i.e. SERCA1a, 
H+-ATPase, Na+/K+-ATPase, Cu2+-ATPase). Mutations in ATP13A2 are associated with PD and Kufor-
Rakeb syndrome, which is a severe early-onset autosomal recessive form of PD with dementia [14]. 
ATP13A2 provides cellular protection against metal toxicity induced by Mn2+ [15,16], Zn2+ [17] and 
Fe3+ [18], which are considered as environmental risk factors of PD. In addition, ATP13A2 provides 
protection in several models of α-synuclein toxicity [15,17]. Although loss of ATP13A2 leads to 
lysosomal dysfunction [19], interestingly, a strong link between ATP13A2 and mitochondrial 
dysfunction/clearance is emerging. Fibroblasts of patients with non-functional ATP13A2 exhibit general 
mitochondrial dysfunction, including decreased ATP production, enhanced oxygen consumption rates 
and fragmentation of the mitochondrial network [20]. Furthermore, knockdown (KD) of ATP13A2 in 
mouse cortical neurons or human neuroblastoma SHSY5Y cells triggers mitochondrial fragmentation 
and ROS production [21], whereas ATP13A2 deficiency in patient-derived olfactory neurosphere 
cultures results in Zn2+ dyshomeostasis, which contributes to mitochondrial dysfunction [17]. Finally, 
in a cellular PD model in which SHSY5Y cells were exposed to the mitochondrial complex I inhibitor 
rotenone to induce mitochondrial stress, ATP13A2 activity confers cytoprotection, since overexpression 
of WT ATP13A2, but not a catalytic dead mutant, protects against, whereas KD of ATP13A2 
exacerbates cell toxicity [22,23]. 
Of interest, the signaling lipids phosphatidic acid (PA) and phosphatidylinositol (3,5) bisphosphate 
(PI(3,5)P2) interact at the ATP13A2 N-terminus and stimulate the auto-phosphorylation reaction, which 
is a hallmark of its catalytic activity [23]. PA is a conical phospholipid that can alter membrane curvature 
or act as a local signaling lipid e.g. produced by phospholipase D (PLD). The phosphoinositide PI(3,5)P2 
is formed by the PIKfyve lipid kinase and mainly resides in the late endo-/lysosomes where it functions 
as an organelle tag. Pharmacological inhibition of PLD (to prevent PA production) or PIKfyve (to 
prevent PI(3,5)P2 generation) counteracts the ATP13A2-mediated protective effect to rotenone-induced 
mitochondrial toxicity [22,23]. Together, these results indicate that PA and PI(3,5)P2 are required for 
the activation of ATP13A2 in conditions of mitochondrial stress. Three putative lipid binding sites 
(LBS1-3) were previously identified in the ATP13A2 N-terminus via protein lipid binding assays with 
purified mutant and WT N-terminal protein fragments of ATP13A2 (Fig. 1A) [23].  
To test whether PA and PI(3,5)P2 are key mediators of the cytoprotective effect of ATP13A2 under 
conditions of mitochondrial stress by direct interaction with and activation of the full length ATP13A2, 
we here compared SHSY5Y cell lines stably expressing WT ATP13A2 or LBS1-3 mutants. We further 
explored whether a similar PA- and PI(3,5)P2-dependent ATP13A2 activation mechanism may also 
provide cellular protection against metal (Mn2+, Zn2+ and Fe3+)-induced cytotoxicity.  
 
  
Materials and Methods 
Cell culture - SHSY5Y neuroblastoma cell lines stably expressing firefly luciferase (FLUC, control), 
WT ATP13A2, mutants of the three putative N-terminal LBS (LBS1: 65FRWKPFAWAP; LBS2: 
74RLRLRALALA; LBS3: 155KRVLRAAVLA; LBS1.2.3: combination of LBS1-3 mutations) or 
sh-ATP13A2 (KD [22,23]) were generated via lentiviral transduction and maintained as described 
previously [23]. 
Drug treatments – Cells were exposed to rotenone (Rot, 1 µM; R8875, Sigma), MPP+ (50 µM, DO48, 
Sigma), Zinc (ZnCl2, 150 µM; Z0152, Sigma), Manganese (MnCl2, 2 µM; 205891000, Acros Organics) 
and Iron (FeCl3, 1.5 mM; 157740, Sigma) for 24 hours (h). The final concentration of each agent was 
chosen from a dose response analysis to obtain a sub-maximal inhibition of cell viability. Prior to 
stressor addition, cells were pre-treated for 1 h with YM-201636 (PIKfyve inhibitor, PIK, 200 nM; 
524611, Millipore) or 5-Fluoro-2-indolyl des-chlorohalopemide  (PLD inhibitor, FIPI, 100 nM; F5807, 
Sigma) to inhibit the production of PI(3,5)P2 or PA, respectively. To inhibit the proteasome, cells were 
incubated with MG-132 (100 µM; M7449, Sigma) for 6 h. 
Fluorescence microscopy - Cells were fixed with 4% para-formaldehyde at 37°C (30 min) and 
permeabilized with 0.1% Triton X-100 at room temperature (10 min). After blocking in PBS containing 
1% BSA and 10% goat serum for 1 h at room temperature, samples were incubated with primary 
antibodies targeting ATP13A2 or LAMP1 (Sigma) overnight at 4°C. Thereafter, samples were washed 
and exposed to Alexa Fluor 488 (green) or Alexa Fluor 647 (red) secondary antibodies. Cells were 
counterstained with DAPI (1 µg/ml) for 10 min, mounted using Prolong Gold antifade reagent and cured 
overnight. Images were acquired with an Olympus IX73 fluorescent microscope using a 63X objective 
and dimension cellSens software. Scale bars represent 10 µM.  
Cell death - Cell death was determined by propidium iodide (PI) exclusion. Briefly, cells were 
trypsinized at the indicated time points and incubated with PI. PI-positive (dead) cells were quantified 
via flow cytometry (Attune Cytometer, Life Technologies). 
Cell viability - Cells were seeded at 5000 cells per well of a 96-well plate. Following treatment cells 
were washed with PBS and incubated with 0.01 mg/ml MUH (4-methylumbelliferyl heptanoate, Sigma) 
dissolved in PBS for 30 min at 37 °C. Fluorescence was measured with a Flex Station plate reader 
(Molecular Devices) with excitation 355 nm, emission 460 nm and cut off value of 455 nm. 
Cellular fractionation - Cells were seeded in 15 cm dishes at a density of 1.5 x 106. After treatment, 
cells were harvested and resuspended in hypotonic buffer [10 mM Tris-HCl pH 7.5, 0.5 mM MgCl2, 
SigmaFast protease inhibitor cocktail (Sigma)] and a 10 min incubation period on ice. Cells were 
homogenized by applying 40 strokes in a Dounce homogenizer and after adding [0.5 M sucrose, 10 mM 
Tris.HCl pH 7.3, 40 µM CaCl2, 0.23 µM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol (DTT)] 20 
additional strokes were performed. The total cell lysate was subjected to differential centrifugation: the 
nuclear fraction (1,000 g; 10 min), the mitochondrial/lysosomal fraction (12,000 g; 20 min) and lastly, 
the microsomal and cytosolic fractions (200,000 g; 35 min; pellet and supernatant, respectively). 
Microsomal pellets were resuspended in a 250 mM sucrose solution supplemented with protease 
inhibitor cocktail. All fractionation steps were carried out at 4°C. After solubilization, samples were 
aliquoted, flash-frozen in liquid nitrogen and stored at -80°C. The protein concentration was determined 
by the Qubit fluorimetric method (Life Technologies). 
Immunoblotting – 10 µg protein of the microsomal fractions was separated on precast NuPAGE 4-12% 
BisTris gels using MOPS running buffer (Life Sciences), followed by transfer onto polyvinylidene 
fluoride membranes (Millipore) according to the manufacturer’s instructions. After blocking in TBS (50 
mM Tris, 150 mM NaCl, pH 7.5) supplemented with 5% non-fat dry milk and 0.1% Tween-20 (Sigma), 
blots were incubated for 1 h with primary polyclonal anti-ATP13A2 (1/1,000 dilution; A3361, Sigma) 
and anti-GAPDH antibodies (1/5,000 dilution; G8795, Sigma), and 45 min with horseradish peroxidase 
conjugated IgG secondary antibodies (1/2,000 dilution; Bioke). Expression was detected using enhanced 
chemiluminescence substrate (Pierce) and the Bio-Rad ChemiDoc MP imaging system. Quantification 
was performed with ImageJ software (http://rsbweb.nih.gov/ij/).   
Auto-phosphorylation assay - 40 µg of the microsomal fraction was added to a final volume of 95 µl 
of reaction buffer (160 mM KCl, 17 mM Hepes, 2 mM MgCl2, 1 mM DTT, 5 mM NaN3). The auto-
phosphorylation assay was started by adding [γ-32P] ATP (2 µCi) and stopped after 1 min with 400 µl 
of ice-cold stop solution (20% trichloroacetic acid, 10 mM phosphoric acid). Samples were incubated 
on ice for 30 min to precipitate protein and centrifuged at 20,000 g for 30 min at 4°C. The pellet was 
washed twice with 400 µl of ice-cold stop solution and finally, dissolved in sample buffer (10% LDS, 
10 mM NaH2PO4, 0.01% SDS, 10 mM 2-mercaptoethanol, 0.15 mg/ml bromophenol blue). After 
loading the samples on NuPAGE 4-12% BisTris gels (Life Sciences), electrophoresis was conducted for 
1.5 h (40 mA, 170 V) in running buffer containing 0.1% SDS and 170 mM MOPS (pH 6.3). Following 
fixation in 7.5% acetic acid, the gel was exposed to a PhosphorImager screen (GE Healthcare) and the 
next day, radioactivity was visualized in a PhosphorImager scanner (Storm 860, GE Healthcare). 
Quantification was performed with Image QuanT (Molecular Dynamics) and ImageJ software packages 
(http://rsbweb.nih.gov/ij/).   
Statistical analysis - Data are presented as the average ± SD of three independent experiments. 
Statistical analysis was conducted by One way Analysis of Variance (ANOVA) with either Dunnett’s 
or Bonferroni post hoc corrections.  */$ P<0.05, **/$$P<0.01, ***/$$$P<0.001. 
 
Results 
LBS2-3 mutations prevent ATP13A2 activation and cytoprotection  
Previously, using purified N-terminal fragments of ATP13A2 in protein lipid overlay assays, we 
described that LBS1 and LBS2 are mainly required for interaction with PI(3,5)P2 (PA to a lesser extent), 
whereas LBS3 is essential for PA interaction [23] (Fig. 1A). Here, we tested whether the protective 
effect of ATP13A2 in conditions of rotenone-induced mitochondrial toxicity can be explained by a 
specific and direct interaction of PI(3,5)P2 and PA to the full-length ATP13A2 protein. To that end, we 
generated stable SHSY5Y cell lines with ATP13A2 KD (75.4±8.9% reduction in ATP13A2 mRNA 
levels as compared to FLUC [23]) or overexpression of FLUC (firefly luciferase, control), ATP13A2 
WT and four mutants in the putative N-terminal lipid binding sites (LBS1, LBS2, LBS3, LBS1.2.3).  
First, we confirmed by immunolocalization that like WT ATP13A2 overexpression, the LBS1, LBS2, 
LBS3 and LBS1.2.3 mutants are also expressed in the LAMP1 positive organelles of the SHSY5Y cells 
(Fig. 1D). Note that the expression of LBS mutants rose well above the endogenous ATP13A2 protein 
levels (FLUC), since the endogenous expression of ATP13A2 in FLUC is only weakly detectable (Fig. 
1D) [23]. These results show that the LBS mutants are expressed in the late endo-/lysosomes to levels 
well above the endogenous ATP13A2, which was confirmed by immunoblotting (Fig. 1B, compare 
FLUC ATP13A2 levels, which fall below the detection limit [23], and LBS mutants). According to the 
immunoblot analysis, the protein levels in the LBS mutant cell lines were at least 10-fold lower than 
WT. This difference in protein expression between WT and LBS mutants was repeatedly observed when 
several WT and LBS1-3 clones were evaluated using various viral vector dilutions. In addition, the 
inhibition of the proteasome by MG-132 only partially enhanced the expression levels of the mutated 
proteins suggesting that protein instability may not be a major issue (Fig. 1B). 
Next, we confirmed that overexpression of ATP13A2 WT protects, whereas KD of ATP13A2 sensitizes 
cells to rotenone (Fig. 2A), in line with our previous findings [23]. Moreover, pharmacological inhibition 
of the PIKfyve lipid kinase by YM-201636 or of the PLD activity by FIPI, prevented the cellular 
protection in ATP13A2 overexpression cell lines, but had no significant effect on the ATP13A2 KD 
cells, suggesting a direct and activating effect of both lipids on ATP13A2 (Fig. 2A). Notably, the 
inhibitors exerted no significant toxic effect in the absence of rotenone (Fig. 2A).  
To further assess the role of ATP13A2 at the level of the mitochondria, we compared the sensitivity of 
our cell lines to rotenone and MPP+, another complex I inhibitor (Fig. 2B-E). Data demonstrated that 
as for rotenone, ATP13A2 WT protects and KD sensitized cells to MPP+ toxicity (Fig. 2D-E).  
Interestingly, in comparison with WT, overexpression of the LBS2, LBS3 and LBS1.2.3 mutants failed 
to protect against either rotenone or MPP+-induced mitochondrial stress, in line with a critical role of 
the LBS2/3 sites in the ATP13A2-mediated cellular protection (Fig. 2B-E). Moreover, compared to 
FLUC, LBS1 demonstrated a slightly weaker than WT, but significant protective effect against rotenone 
or MPP+ in the cell viability assay. In contrast to rotenone, the protection of LBS1 to MPP+ was not 
significant in the cell death assay (Fig. 2B-C). The failure of the LBS2-3 mutants to protect against 
either rotenone or MPP+ is not merely related to their lower expression levels, since for either cell death 
induction (Fig. 2B&D) or inhibition of cell viability (Fig. 2C&E) a significant sensitization to either 
agent was observed in the LBS2, LBS3 and LBS1.2.3 cell lines to the level of ATP13A2 KD, whereas 
in LBS1 such a sensitization was not observed. Finally, we tested whether mutagenesis of the key lipid 
interacting sites influenced the auto-phosphorylation properties of ATP13A2 (Fig. 1C). No auto-
phosphorylation signal was observed in the LBS2/3/1.2.3 cells, whereas in LBS1 cells a faint, but 
reproducible auto-phosphorylation signal was detected. 
Altogether, these data point to an inhibitory effect of the LBS2-3 mutations on the functionality of 
ATP13A2 in conditions of mitochondrial stress. 
PA and PI(3,5)P2 mediated protection against mitochondrial stress occurs specifically via 
ATP13A2 
We investigated whether pharmacological inhibition of PA and PI(3,5)P2 production may influence the 
response of the LBS cell lines to rotenone-induced mitochondrial stress (Fig. 3). In the LBS1 and LBS3 
cell lines, inhibition of PIKfyve by YM-201636 significantly increased rotenone-induced toxicity (Fig. 
3A-B). In contrast, YM-201636 exposure was unable to incite further stress in either the LBS2 or 
LBS1.2.3 cell lines. In the case of PA, inhibition of PLD by FIPI was unable to potentiate the rotenone-
elicited toxicity in LBS3 and LBS1.2.3 (Fig. 3C-D). Yet for the LBS1 cells, FIPI significantly 
potentiated rotenone-induced toxicity (Fig. 3C-D), whereas in the case of LBS2, a significant effect of 
FIPI was only observed in the cell viability assay (Fig. 3C). These observations correlate well with 
previous observations that PI(3,5)P2 predominantly interacts with LBS2 and PA with LBS3 [23]. 
Altogether, these data are in line with an inhibitory effect of the N-terminus on ATP13A2 activity, which 
is reversed by specific and direct binding of PA and PI(3,5)P2 to the LBS sites in conditions of rotenone-
induced mitochondrial stress. 
PA and PI(3,5)P2 provide ATP13A2-mediated protection to PD-related metal toxicity 
The protective effect of ATP13A2 to various metal ions (Mn2+ [15,16], Zn2+ [17] and Fe3+ [18]) depends 
on the catalytic activity of ATP13A2, since a catalytic dead mutant is unable to provide cellular 
protection. Here, we tested whether the activation of ATP13A2 during metal toxicity also depends on 
PA and/or PI(3,5)P2. In the stable SHSY5Y cell lines we observed that similar to rotenone and MPP+ 
toxicity ATP13A2 overexpression protected against, whereas KD sensitized cells to metal toxicity 
following exposure to Zn2+, Mn2+ and Fe3+ (Fig. 4A-B), in line with previous reports [15,16,18,22,23].  
Next, we addressed whether the ATP13A2-mediated protection to metal toxicity also depends on PA 
and PI(3,5)P2 interaction. Similar as in conditions of rotenone (Fig. 2A), inhibition of PI(3,5)P2 
formation significantly blunted the protective effect following metal exposure observed in both FLUC 
and WT overexpression cells, but not in the KD cell line (Fig. 4C-E). Like the data obtained for YM-
201636, FIPI also blunted the protective effect of ATP13A2 to the metal ions Zn2+, Mn2+ and Fe3+ (Fig. 
4C-E). However, unlike YM-201636, FIPI increased the sensitivity of FLUC and WT overexpression 
cells up to the level of the ATP13A2 KD cells, whereas co-exposure of YM-201636 and FIPI did not 
further potentiate cell death. Finally, in ATP13A2 KD cells YM-201636 or FIPI did not exert an effect 
on metal ion toxicity, whereas in all cell lines treatment with either YM-201636 or FIPI alone did not 
induce cell death (Fig. 4C-E).  
In addition, the LBS1-3 cells were exposed to the metal ions Zn2+ or Mn2+, and cytotoxicity and cell 
death were assessed (Fig. 5). Compared to ATP13A2 WT and FLUC, LBS3 and LBS1.2.3 showed a 
significant loss in the protective effect of ATP13A2 towards either Zn2+ or Mn2+ (Fig. 5A-D). Although 
LBS2 demonstrated a significant, albeit small, reduction in the protective capacity based on the cell 
death assay, no significant difference was found for LBS2 in the cell survival assay, suggesting that the 
sensitization to heavy metal toxicity was most consistent and significant in the LBS3 cell line. 
  
Discussion 
Inhibition of ATP13A2 activity by the N-terminus is reversed by PA and PI(3,5)P2 interaction 
The catalytic activity of ATP13A2 provides cellular protection against various PD-related insults like 
mitochondrial stress [22,23] and metal exposure (Mn2+ [15,16], Zn2+ [17] and Fe3+ [18]). Here we 
established that these various cytoprotective effects depend on the same activation mechanism of 
ATP13A2 involving an N-terminal lipid switch. Our results show that both PI(3,5)P2 and PA are 
required to exert ATP13A2 mediated cellular protection, which is explained by a specific and direct 
interaction of PI(3,5)P2 and PA at the ATP13A2 N-terminal lipid binding sites LBS2 and LBS3, 
respectively.   
Whereas LBS1.2.3 mutants do not respond to either PIKfyve or PLD inhibition, pharmacological 
inhibition of PIKfyve or PLD had no impact on rotenone toxicity in respectively the LBS2 and LBS3 
cell lines, strongly indicating that PI(3,5)P2 binds to LBS2 and PA to LBS3. This is in agreement with 
previous results of protein lipid overlays with purified N-terminal fragments of ATP13A2 [23]. In 
addition, our data demonstrate that both lipids need to bind together to allow ATP13A2 activation, since 
pharmacological inhibition of only PA or PI(3,5)P2 formation is sufficient to abolish the cellular 
protection of ATP13A2 WT to rotenone. No auto-phosphorylation signal was detected for the 
LBS2/3/1.2.3 mutants, whereas a weak signal was detected for LBS1, suggesting that the LBS2/3/1.2.3 
mutants might exhibit loss of auto-phosphorylation activity. However, we cannot fully exclude that the 
auto-phosphorylation signal might have fallen below the detection level of the assay due to the lower 
expression levels of the mutants. But since we previously demonstrated that application of PA and 
PI(3,5)P2 stimulate the auto-phosphorylation reaction [23] and we now show that the protective effects 
of ATP13A2 depend on lipid interactions on LBS2/3, it is reasonable to speculate that the functional 
LBS2-3 sites are required for the catalytic auto-phosphorylation reaction. 
Together, our observations highlight the critical dependence of ATP13A2 activation on the lipid 
interactions at the membrane-associated N-terminal domain and suggest that the N-terminus might be 
an auto-inhibitory domain preventing ATP13A2 activity. Auto-inhibition of P-type ATPases by N- or 
C-terminal regions is frequently observed, e.g. in the human plasma membrane Ca2+-ATPase PMCA 
[24] and the proton pump in plants [25]. 
Surprisingly, the LBS2/3/1.2.3, but not LBS1 cell lines displayed an increased sensitivity to either 
rotenone or MPP+ in comparison to FLUC control cells, and reached similar toxicity levels as observed 
for KD cells. This result may point to a dominant negative effect of the LBS2/3/1.2.3 mutants 
suppressing the protective effect of the endogenous ATP13A2. Of interest, this dominant negative effect 
was not observed with LBS1 (Fig. 2) or the catalytic dead mutant D508N [23], which both contain intact 
LBS2/3 sites. The LBS2/3 mutated N-terminus might therefore inhibit the endogenous ATP13A2 by 
direct interaction, or by irreversibly trapping regulatory proteins and/or lipids required for ATP13A2 
activation. Alternatively, the endogenous WT ATP13A2 levels might be reduced upon expression of the 
LBS2/3/1.2.3 mutants, which might also explain why the LBS mutant cell lines display an increased 
sensitivity to mitochondrial stress as compared to control cells. These possibilities will be addressed in 
future experiments. 
Lysosomal and mitochondrial dysfunctions are tightly connected in PD 
So far the exact cellular function of ATP13A2 remains obscure, since the transported substrate of 
ATP13A2 is not yet identified. However, a role of ATP13A2 in the clearance of mitochondria and 
proteins is gradually emerging. ATP13A2 is involved in the biogenesis and release of exosomes 
mediating α-synuclein clearance [17], whereas a role of ATP13A2 in autophagy-dependent pathways 
has also been proposed, although mechanistic details are lacking [20,21,26]. Indeed, ATP13A2 KD in 
SHSY5Y cells reduces autophagic flux [21], whereas lysosomal mediated clearance of autophagosomes 
is impaired in patient-derived ATP13A2−/− fibroblasts [19]. A decreased autophagic flux associated with 
ATP13A2 deficiency may critically affect mitochondrial quality control, which may explain 
mitochondrial fragmentation and elevated ROS production [21].  
Of interest, the dependency of ATP13A2 activation on PA and PI(3,5)P2 further connects ATP13A2 to 
autophagy-mediated clearance pathways [22,23]. Indeed, PLD1 regulates α-synuclein clearance via 
autophagy [27], whereas PI(3,5)P2 regulates endo-/lysosome morphology and is also implicated in 
autophagy [28,29]. By stimulating ATP13A2 activity both lipids might regulate autophagy and promote 
mitochondrial quality control and overall cellular health. ATP13A2 activity might be specifically 
required in conditions of mitochondrial stress and damage, which can be induced by various insults, 
such as the complex I inhibitors rotenone/MPP+ or also by toxic concentrations of Zn2+, Mn2+ or Fe3+ 
[30,31]. Indeed, loss of ATP13A2 in olfactory neurosphere cultures results in Zn2+ dyshomeostasis, 
which on its term contributes to mitochondrial dysfunction [17]. 
PD studies highlight the importance of mitochondrial maintenance and clearance by PINK1/parkin 
mediated mitophagy, a macro-autophagy pathway involving the encapsulation of defective 
mitochondria in autophagosomes [32-34]. But how lysosomes accept the mitochondria for subsequent 
degradation via mitophagy pathways or alternative routes such as mitochondrial derived vesicles [35], 
and what the role of ATP13A2 is herein, remains poorly understood. Nevertheless, lysosomal and 
mitochondrial dysfunctions may be tightly connected in PD. Besides ATP13A2, also mutations in the 
lysosomal protein glucocerebrosidase (GBA) are genetic risk factors for PD leading to impaired 
lysosomal sphingolipid degradation, mitochondrial fragmentation and elevated ROS levels [36]. In 
addition, LRRK2 affects both lysosomal functionality and regulates mitochondrial dynamics [37,38].  
In conclusion, PA and PI(3,5)P2 are required for ATP13A2-mediated protection to rotenone/MPP+-
induced mitochondrial stress and toxic Mn2+/Zn2+/Fe3+ concentrations, suggesting a general lipid-
dependent ATP13A2 activation mechanism that relieves the N-terminal auto-inhibition. Thus, targeting 
the N-terminal lipid binding sites of ATP13A2 might offer a therapeutic modality to activate ATP13A2 
and reduce cellular toxicity of various PD insults. 
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Figure Legends 
Fig. 1. Mutations in the key lipid binding sites of ATP13A2 inhibit activity but not subcellular 
targeting 
(A) Multiple positively charged residues in previously identified lipid binding sites [23] (black, 
underlined) were substituted for Ala. LBS3 overlaps with an alternative splicing site rendering an 
insertion of five additional residues in splice variant 1 of ATP13A2. Ma, membrane-associated region. 
(B) Expression levels of ATP13A2 were analyzed by immunoblotting with a primary anti-ATP13A2 
antibody in comparison to GAPDH as a loading control. Breakdown of LBS mutant proteins by the 
proteasome was assessed via treatment with the proteasome inhibitor MG-132 (100 µM) for 6 h. The 
same gel for the expression of ATP13A2 between cell lines has been provided at both low and high 
intensities. OE, overexpression. (C) Auto-phosphorylation assay (EP) on microsomes of ATP13A2 WT 
or LBS mutant expressing SHSY5Y cells. Top, the same gel was depicted twice at different exposure 
times. Below, equal protein loading on the SDS-PAGE gel was confirmed by coomassie staining. We 
consider that the double bands visible in LBS2 and LBS3 at longer exposure time are background levels 
while the actual ATP13A2 related EP band (visible in LBS1 and WT-OE) is located in between, but 
closer to the double band. Quantification of ATP13A2 expression ((B) ATP13A2/GAPDH) and auto-
phosphorylation levels ((C) EP/coomassie) are depicted. (D) Expression and localization of endogenous 
(FLUC), WT-OE, LBS1, LBS2, LBS3 or LBS1.2.3 ATP13A2 were confirmed by co-localization 
experiments with the lysosomal marker LAMP1 and captured using Olympus IX73 fluorescent 
microscope. Representative enlarged images of co-localization for all cell lines have been provided as 
image inserts. Data are representative of 3 independent experiments. Scale bars represent 10 µM.  
Fig. 2. LBS mutations prevent ATP13A2 mediated cytoprotection 
(A) ATP13A2’s protective response at 24 h exposure to rotenone (Rot, 1 µM) and the effect of 
pharmacological inhibition of PIKfyve lipid kinase with YM-201636 (PIK or P, 200 nM) and inhibition 
of PLD with FIPI (F, 100 nM) on cell death were assessed via a Propidium Iodide (PI) based assay. $ 
Statistical differences between FLUC and WT-OE/shATP13A2, * Statistical differences within cell line 
following treatment with inhibitor (1 mark, P < 0.05; 2 marks, P < 0.01; 3 marks, P < 0.001) (ANOVA 
with Bonferroni post hoc test). (B-E) Stable cell lines were exposed to 1 µM rotenone (B-C) or 50 µM 
MPP+ (D-E) for 24 h and cell death was assessed by PI stained flow cytometry, whereas cell viability 
was assayed by the MUH protocol. Data are the mean of 3 independent experiments ± SD. * Statistical 
differences between FLUC and WT-OE/shATP13A2/LBS1/LBS2/LBS3/LBS1.2.3 (1 mark, P < 0.05; 
2 marks, P < 0.01; 3 marks, P < 0.001) (ANOVA with Bonferroni post hoc test).  
Fig. 3. PA and PI(3,5)P2 mediated protection to mitochondrial stress occurs via ATP13A2 
SHSY5Y cells stably expressing FLUC, shRNA for KD of ATP13A2, ATP13A2 and full length mutants 
of ATP13A2 with mutated putative lipid binding sites (LBS1-3) were exposed to rotenone (Rot, 1 µM) 
in the presence or absence of 1 h pretreatment with the pharmacological inhibitors of PIKfyve lipid 
kinase (A & B, YM-201636, 200 nM) or phospholipase D (C &D, FIPI, 100 nM). Following 24 h 
exposure to rotenone, cells were assessed for cell viability (A & C) or death (B & D) by respectively 
MUH and Propidium Iodide (PI) assays. Data are the mean of 3 independent experiments ± SD. $ 
Statistical differences between FLUC and WT-OE/shATP13A2/LBS1/LBS2/LBS3/LBS1.2.3, * 
Statistical differences within cell line following treatment with inhibitor (1 mark, P < 0.05; 2 marks, P 
< 0.01; 3 marks, P < 0.001) (ANOVA with Bonferroni post hoc test). 
Fig. 4. PA and PI(3,5)P2 provide ATP13A2-mediated protection to PD-related metal toxicity 
(A-B) The SHSY5Y cell models stably overexpressing FLUC, WT-OE or shATP13A2 were exposed 
for 24 h to rotenone (Rot, 1 µM, positive control) and MPP+ (50 µM), as well as the heavy metals Zn2+ 
(150 µM), Mn2+ (2 µM) and Fe3+ (1.5 mM). Cell viability was evaluated by the MUH assay (A), whereas 
cell death was assessed by Propidium Iodide (PI) stained flow cytometry (B). To test whether the 
protective role of ATP13A2 depends on the signaling lipids PI(3,5)P2 and PA, the SHSY5Y cell lines 
were pre-treated for 1 h with the PIKfyve inhibitor (200 nM; P or PIK) and/or the phospholipase D 
inhibitor (100 nM; F or FIPI) prior to the addition of the heavy metals Zn2+ (C), Mn2+ (D) and Fe3+ (E). 
The level of cellular protection was evaluated by PI stained flow cytometry. Data are the mean of 3 
independent experiments ± SD. $ Statistical differences between FLUC and WT-OE, * Statistical 
differences within cell line following treatment with inhibitor (1 mark, P < 0.05; 2 marks, P < 0.01; 3 
marks, P < 0.001) (ANOVA with Bonferroni post hoc test). 
Fig. 5. The capacity of ATP13A2 to interact with PA/PI(3,5)P2 is essential to protect against heavy 
metal-induced cytotoxicity  
SHSY5Y cell lines stably overexpressing FLUC, ATP13A2 shRNA, ATP13A2 WT and LBS1-3 
mutants were exposed to toxic heavy metal concentrations of Zn2+ (150 µM, A & B) or Mn2+ (2 µM, C 
& D). Cell death induction was assessed by Propidium Iodide (PI) -based flow cytometry (A & C), 
whereas cell viability by MUH assay (B & D). Data are the mean of 3 independent experiments ± SD. 
* Statistical differences between FLUC and WT-OE/shATP13A2/LBS1/LBS2/LBS3/LBS1.2.3 (1 
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